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Reply to Me´nasche´ et al.
To the Editor:
It is gratifying to learn that Me´nasche´ et al. (2002 [in
this issue]) agree with our analysis of the phenotypic
differences between patients with RAB27A mutations
and those with MYO5A mutations. We leave it to Jour-
nal readers to decide if previous publications have “un-
equivocally established” these points. We do apologize
for the error in table 1, which we recognized and have
corrected in an erratum.
Perhaps we could make two additional points. First,
Gaucher disease types I, II, and III represent examples
of defects in a single gene resulting in different pheno-
types, whereas Griscelli/Elejalde syndromes represent ex-
amples of defects in two different genes resulting in phe-
notypes with some similarities. Second, we wonder what
nomenclature should be employed for these two disor-
ders. Me´nasche´ et al. continue to use Griscelli syndromes
types 1 and 2. However, Griscelli’s original cases exhib-
ited immune deficiency (Griscelli et al. 1978), whereas
Elejalde first recognized a distinct, neurologically based
disorder (Elejalde et al. 1979). Perhaps Dr. Elejalde
should be credited for the accuracy of his ascertainment.
MARJAN HUIZING,1 Y. ANIKSTER,2 AND W. A. GAHL1
1Section on Human Biochemical Genetics, Medical
Genetics Branch, National Human Genome Research
Institute, National Institutes of Health, Bethesda,
MD; and 2Metabolic Unit, Sheba Medical Center, Tel
Hashomer, Israel
References
Elejalde BR, Holguin J, Valencia A, Gilbert EF, Molina J, Ma-
rin G, Arango LA (1979) Mutations affecting pigmentation
in man. I. Neuroectodermal melanolysosomal disease. Am
J Med Genet 3:65–80
Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog
C, Prunicras M. (1978) A syndrome associating partial al-
binism and immunodeficiency. Am J Med 65:691–702
Me´nasche´ G, Fischer A, de Sainte Basile G (2002) Griscelli
syndrome type 1 and 2. Am J Hum Genet 71:1237–1238
(in this issue)
Address for correspondence and reprints: Dr. Marjan Huizing, 10 Center
Drive, MSC 1851, Building 10, Room 10C-103, National Human Genome Re-
search Institute, National Institutes of Health, Bethesda, MD 20892-1851. E-
mail: mhuizing@mail.nih.gov
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7105-0027$15.00
Am. J. Hum. Genet. 71:1238–1239, 2002
Family-Based Association Tests Incorporating Parental
Genotypes
To the Editor:
The report “Parental Genotypes in the Risk of a Com-
plex Disease” (Labuda et al. 2002) gives several inter-
esting examples of how parental genotypes can contrib-
ute to children’s disease risk—for example, through
maternal effects during pregnancy or paternal effects
during spermatogenesis. The authors note that if disease
risk depends on parents’ genotypes but not their child’s
genotype, then the distribution of genotypes in cases will
not differ from the Mendelian expectation given their
parents’ genotypes. Hence, the traditional transmission
disequilibrium test (TDT) using case-parent trio data will
(correctly) not detect any association between individ-
uals’ genotypes and disease. The authors present an ex-
ample in which the TDT provides no evidence of an
association between a variant allele and disease (in fact,
the point estimate for the odds ratio is 1.0), whereas a
comparison of case subjects’ genotypes to those of pop-
ulation control subjects does provide evidence of asso-
ciation (estimated odds ratio p 3.4). The authors then
compare maternal and paternal genotypes to control
subjects’ genotypes and find evidence that the prevalence
of the variant allele is higher in parents of case subjects
than in population control subjects.
However, there are other analytic options in this
case—namely, flexible statistical methods for case-parent
trios which can test for parental-genotype effects. These
have the advantage of being robust to population-strat-
ification bias and, in some situations, are even more
powerful for testing for parental-genotype effects than
case-control studies (Starr et al. 2002).
The log-linear model developed by Weinberg et al. and
Wilcox et al. can test for parental-genotype and parent-
of-origin effects after adjusting for possible case-geno-
type effects (Weinberg et al. 1998; Wilcox et al. 1998).
In principle, this model can also test parental-genotype
# case-genotype interactions—which could be relevant;
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for example, in the study of complications during preg-
nancy such as preeclampsia (Kilpatrick 1999).
The log-linear model is equivalent to a conditional
logistic analysis comparing the case to appropriately de-
fined “pseudo-sibling controls” (Kraft 2002). If the gene
under study is assumed not to play a direct role in an
individual’s risk of disease (or to be linked to any other
such gene), then to test for an indirect role of maternal
genotype (say) each case subject should be compared to
a pseudo-sibling control subject whose mother has the
genotype of the case subject’s father. That is, if the ge-
notypes of the mother and father are Gm and Gf, re-
spectively, then the conditional logistic likelihood for the
family is
bZ(G )me
,
bZ (G ) bZ(G )m fe  e
where Z(7) is some dominance coding.
This approach (reasonably) assumes that, given the
set of parental marker genotypes {G1,G2}, it is equally
likely that Gm p G1 or G2. In other words, “the fre-
quency of heterozygous mothers married to homozygous
variant fathers is the same as the frequency of hetero-
zygous fathers married to homozygous variant mothers,
and so on” (Wilcox et al. 1998). Furthermore, since this
likelihood permutes the genotypes of “the parent con-
tributing to disease risk” and the “the parent not con-
tributing to disease risk,” it cannot estimate joint effects
of both parents’ genotypes. However, for many diseases,
only the mother (father) will plausibly contribute to a
child’s disease risk.
Although the case-parent trio analysis conditions on
the parents’ genotypes and hence is robust to population
stratification bias, the analysis comparing parental ge-
notypes to population-based controls is not (although
Labuda et al. [2002] argue that this may not be an issue
for the particular data they analyze in their report). Fur-
thermore, even when there is no population stratifica-
tion, the latter analysis is something of an “apples and
oranges” comparison, as the exposure of interest is not
the control subject’s genotype, but his or her parent’s
genotype. The control’s genotype serves as a surrogate
for his or her parent’s. In a simulation study with 175
unmatched case and control subjects (1,000 replicates),
we found that the odds ratio comparing case subjects’
maternal genotypes to control genotypes underestimated
the odds ratio associated with each variant maternal
allele by 11% (variant allele frequency 0.25; baseline
probability of disease 14%; odds ratio per variant ma-
ternal allele 2). Of course, the data Labuda et al. (2002)
analyzed did not contain parental genotype information
for the controls. But if one were to design a case-pop-
ulation control study to detect the effects of maternal
(paternal) genotypes, then one should plan to collect
information on controls’ maternal (paternal) genotypes.
Finally, figure 1a is misleading in that case subjects’
parents are not representative of population controls if
individuals’ genotypes are associated with disease or
there is population stratification.
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Regarding “Parental Genotypes in the Risk of a
Complex Disease”
To the Editor:
Labuda et al. (2002) have proposed that parental ge-
notypes might play a role in the causation of complex
diseases. They seem unaware that this idea has been
considered by others (e.g., Lande et al. 1989) and that
methods have been developed to test for parentally me-
diated genetic effects, both for a dichotomous phenotype
(Mitchell 1997; Weinberg et al. 1998; Wilcox et al.
